jeudi 21 novembre 2019

Onco Actu du 21 novembre 2019


1. BIOLOGIE



How do gliomas evolve? [The Jackson Lab]











1.4 BIOLOGIE - TECHNOS, MODÈLES



Genome editing: a broad perspective on a precision technology [PHG Foundation]











2.5 ETIOLOGIE - GÈNES



Researchers identify new gene mutation in familial thyroid cancers [Penn State]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Massachusetts State Senate Votes to Ban Almost All E-Cigarettes, But to Leave the Real Deadly Ones on the Shelves [The Rest of the Story]











Trump’s F.D.A. Nominee Sidesteps Questions About Banning Flavored Vaping Products [NY Times]











White House: Vaping rules not stalled, Trump plans Friday meeting [Reuters]











Canadian teen developed 'popcorn lung' type injury from vaping: report [Reuters]











Up in smoke: are we wrong about the dangers of vaping? [The Guardian]










4.12 BIOPSIES LIQUIDES



Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow [Xconomy]











4.9 DÉP., DIAG. & PRONO. - SEIN



Lower Cutoff Score for Oncotype DX Test May Be Needed for Male Breast Cancer Patients [Genome Web]











Oncotype DX Breast Recurrence Score Reveals Sex-related Differences in Mortality Prediction in Patients With Early-stage ER-positive Breast Cancer [AACR]










5. TRAITEMENTS



Adding Isatuximab to Pomalidomide and Low-Dose Dexamethasone Improves PFS in Relapsed and Refractory Multiple Myeloma [ESMO]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Taking a moonshot at a rare childhood cancer [MIT]











Scientists discover new drugs with potential to treat stubborn cancers [University of Alberta]











Scientists find promising drug combination against lethal childhood brain cancers [NIH]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player Dragonfly [EndPoints]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Letting academic medical centers make CAR-T drugs would save billions [STAT]










5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Bristol's Opdivo-Yervoy combo fails to top Opdivo in adjuvant melanoma [Fierce Pharma]










Opdivo/Yervoy combo for melanoma fails in key patient population [EndPoints]











Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1% [BMS]











Bristol-Myers misses main goal of late-stage skin cancer trial [Reuters]











5.12.6 IMMUNOTHÉRAPIES - AMM



European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) [Merck]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst [Fierce Pharma]











5.2.1 PHARMA - PARTENARIATS



Sanofi to assimilate Aetion's real-world data platform into its own [Fierce Biotech]










Sanofi and Aetion launch enterprise-wide collaboration to advance regulatory submissions using real-world evidence [Sanofi]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company [BMS]











5.3 TRAITEMENTS - FDA, EMA, NICE...



FDA Commissioner nominee Hahn promises to put science above politics [Fierce Pharma]











Stephen Hahn, Trump’s FDA nominee, pledges ‘bold action’ on vaping but sidesteps questions on flavor ban [STAT]











6.11 PATIENTS



Patients Need More Education Regarding the Purpose of Precision Medicine Trials [AJMC]











6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



Herbal Products and Cancer Treatment [Science-Based Medicine]











6.6 PUBLICATIONS



The science institutions hiring integrity inspectors to vet their papers [Nature]










6.7.1 IA/BIOINFORMATIQUE



How To Deal With Machine Learning Papers [In The Pipeline]